Cytokine Storm
52
1
2
28
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.8%
3 terminated out of 52 trials
90.3%
+3.8% vs benchmark
8%
4 trials in Phase 3/4
11%
3 of 28 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 28 completed trials
Clinical Trials (52)
Jafron Cytokine Adsorber During Pediatric Open-Heart Surgeries
Anakinra in Dengue With Hyperinflammation ( AnaDen )
CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19
Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS
MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis
Fluoxetine to Reduce Intubation and Death After COVID19 Infection
Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes
UNITE Study (UMN-GE) for COVID-19
UNITE Study (UMN-SW) for COVID-19
Prospective Study for the Application of Cytosorb® in Critically Ill Patients
Interleukin-34 in Stage I and II Periodontitis
Early Treatment of Cytokine Storm Syndrome in Covid-19
Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure
Relationship Between Oral Findings and Salivary Factors in Sars-Cov-2 Patients
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
Effect of Pentoxifylline on Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection
Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
Non-invasive Nervus Vagus Stimulation in Patients With COVID-19 and ARDS
Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis